Work

Development of engineered antibodies specific for the Mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer

Year: 2006

Type: article

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.mct-06-0115

Authors: Qing-an Yuan, Heidi H. Simmons, Matthew K. Robinson, Maria Russeva, Wayne A. Marasco, Gregory P. Adams

Institutions: Fox Chase Cancer Center, Harvard University, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute

Award: FCCC-PENN SPORE in Ovarian Cancer

OpenAlex ID: W2104455255

FWCI: 2.15

Cites: 61

Cited by: 25

Related to: 10